Unveiling CCL2 and CXCL1: Key biomarkers and therapeutic targets in idiopathic pulmonary fibrosis

Jing  Pan; Guanhua  Li; Yuanyuan  Pu; Peilin  Li; Yan Zhou

doi:10.36141/svdld.v42i4.17182

Authors

Jing Pan Department of Respiratory and Critical Care Medicine, Affiliated Central Hospital of Shandong First Medical University, Jinan, China
Guanhua Li Department of Respiratory and Critical Care Medicine, Affiliated Central Hospital of Shandong First Medical University, Jinan, China
Yuanyuan Pu Department of Respiratory and Critical Care Medicine, Affiliated Central Hospital of Shandong First Medical University, Jinan, China
Peilin Li Department of Plastic and Cosmetic Surgery‌, Tsinghua University Yuquan Hospital, Beijing, China
Yan Zhou Department of Infectious Diseases, Affiliated Central Hospital of Shandong First Medical University, Jinan, China

Keywords:

idiopathic Pulmonary Fibrosis (IPF), Alveolar Macrophages, Differentially Expressed Genes (DEGs), Biomarkers, Inflammatory Pathways

Abstract

Idiopathic Pulmonary Fibrosis (IPF) is a chronic, progressive lung disease characterized by fibrosis and impaired lung function. Understanding the molecular mechanisms underlying IPF is crucial for developing effective therapeutic strategies. This study aims to identify differentially expressed genes (DEGs) in alveolar macrophages of IPF patients and validate these findings in an independent cohort. We analyzed gene expression data from the GSE49072 dataset, which includes 23 IPF and 61 normal alveolar macrophage samples. Differential expression analysis was performed using the LIMMA package, and Gene Set Enrichment Analysis (GSEA) identified significant biological pathways. Validation of key DEGs (CCL2, CCL7, and CXCL1) was conducted using ELISA in serum samples from an independent cohort of 50 IPF patients and 50 normal controls. Correlations with clinical parameters such as forced vital capacity (FVC) and diffusing capacity for carbon monoxide (DLCO) were also evaluated. The analysis identified several DEGs, with CCL2 and CXCL1 showing significant upregulation in IPF samples. GSEA highlighted pathways related to inflammatory responses and extracellular matrix remodeling. ELISA validation confirmed elevated serum levels of CCL2 and CXCL1 in IPF patients, correlating with reduced FVC and DLCO. CCL7 did not show significant differences between groups. Targeting these chemokines may offer new therapeutic avenues for IPF treatment. Further research is needed to explore the therapeutic potential and validate findings in larger cohorts. This study enhances our understanding of IPF pathogenesis and identifies promising targets for clinical intervention.

References

1. Sgalla G, Iovene B, Calvello M, Ori M, Varone F, Richeldi L. Idiopathic pulmonary fibrosis: pathogenesis and management. Respir Res. 2018;19(1):32. doi: 10.1186/s12931-018-0730-2.

2. Martinez FJ, Collard HR, Pardo A, et al. Idiopathic pulmonary fibrosis. Nat Rev Dis Primers. 2017;3:17074. doi: 10.1038/nrdp.2017.74.

3. Raghu G. Idiopathic pulmonary fibrosis: lessons from clinical trials over the past 25 years. Eur Respir J. 2017;50(4). doi: 10.1183/13993003.01209-2017.

4. Somogyi V, Chaudhuri N, Torrisi SE, Kahn N, Müller V, Kreuter M. The therapy of idiopathic pulmonary fibrosis: what is next? Eur Respir Rev. 2019;28(153). doi: 10.1183/16000617.0021-2019.

5. George PM, Patterson CM, Reed AK, Thillai M. Lung transplantation for idiopathic pulmonary fibrosis. Lancet Respir Med. 2019;7(3):271-82. doi: 10.1016/s2213-2600(18)30502-2.

6. Joshi N, Walter JM, Misharin AV. Alveolar Macrophages. Cell Immunol. 2018;330:86-90. doi: 10.1016/j.cellimm.2018.01.005.

7. Shi T, Denney L, An H, Ho LP, Zheng Y. Alveolar and lung interstitial macrophages: Definitions, functions, and roles in lung fibrosis. J Leukoc Biol. 2021;110(1):107-14. doi: 10.1002/jlb.3ru0720-418r.

8. Krafft E, Lybaert P, Roels E, et al. Transforming growth factor beta 1 activation, storage, and signaling pathways in idiopathic pulmonary fibrosis in dogs. J Vet Intern Med. 2014;28(6):1666-75. doi: 10.1111/jvim.12432.

9. Shi Y, Gochuico BR, Yu G, et al. Syndecan-2 exerts antifibrotic effects by promoting caveolin-1-mediated transforming growth factor-β receptor I internalization and inhibiting transforming growth factor-β1 signaling. Am J Respir Crit Care Med. 2013;188(7):831-41. doi: 10.1164/rccm.201303-0434OC.

10. Smyth GK. Limma: linear models for microarray data. Bioinformatics and computational biology solutions using R and Bioconductor: Springer; 2005. p. 397-420. doi: 10.1007/0-387-29362-0_23.

11. Kuleshov MV, Jones MR, Rouillard AD, et al. Enrichr: a comprehensive gene set enrichment analysis web server 2016 update. Nucleic Acids Res. 2016;44(W1):W90-7. doi: 10.1093/nar/gkw377.

12. Wickham H. ggplot2. Wiley interdisciplinary reviews: computational statistics. 2011;3(2):180-5. doi: 10.1002/wics.147.

13. Deshmane SL, Kremlev S, Amini S, Sawaya BE. Monocyte chemoattractant protein-1 (MCP-1): an overview. J Interferon Cytokine Res. 2009;29(6):313-26. doi: 10.1089/jir.2008.0027.

14. Gui X, Qiu X, Tian Y, et al. Prognostic value of IFN-γ, sCD163, CCL2 and CXCL10 involved in acute exacerbation of idiopathic pulmonary fibrosis. Int Immunopharmacol. 2019;70:208-15. doi: 10.1016/j.intimp.2019.02.039.

15. Korbecki J, Barczak K, Gutowska I, Chlubek D, Baranowska-Bosiacka I. CXCL1: Gene, Promoter, Regulation of Expression, mRNA Stability, Regulation of Activity in the Intercellular Space. Int J Mol Sci. 2022;23(2). doi: 10.3390/ijms23020792.

16. Schupp JC, Binder H, Jäger B, et al. Macrophage activation in acute exacerbation of idiopathic pulmonary fibrosis. PLoS One. 2015;10(1):e0116775. doi: 10.1371/journal.pone.0116775.

17. Horuk R. Chemokine receptor antagonists: overcoming developmental hurdles. Nat Rev Drug Discov. 2009;8(1):23-33. doi: 10.1038/nrd2734.